Our Pipeline

Our product pipeline includes two cell-based and two drug-based therapeutic products in development. It also includes currently-marketed online database products and research products outlined below.
The AgeX product pipeline. T2D (Type II Diabetes), MI (Myocardial Infarction), CHF (Congestive Heart Failure), EFT (Embryonic-Fetal Transition), Dx (Diagnosis), Tx (Therapy).
Our lead cell-based therapeutic candidates in development are AGEX-BAT1 and AGEX-VASC1:


AGEX-BAT1 is our preclinical cell therapy product candidate utilizing PSC-derived brown adipocytes for the treatment of certain age-related metabolic disorders such as Type II (adult-onset) diabetes.


AGEX-VASC1 is a cell-based therapy in the preclinical stage of development comprised of young regenerative vascular-forming cells formulated in our proprietary HyStem™ matrix. AGEX-VASC1 is designed to restore vascular support in aged ischemic tissues such as the aging heart.
Our lead drug-based therapeutic candidates in development are AGEX-iTR1547 and Renelon:


AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using our proprietary iTR™ technology.


Renelon™ is a first-generation iTR product candidate designed to promote scarless tissue repair and is planned to be developed as a topically-administered device for commercial development.
In addition, cancer diagnostic and therapeutic applications of iTR technology are planned for development through partnering with third parties.

AgeX products for Stem Cell Research and Drug Safety Testing

A Subsidiary of:

A Subsidiary of:

AgeX products for Stem Cell Research and Drug Safety Testing